Proficio Capital Partners LLC Purchases Shares of 39,742 U.S. Physical Therapy, Inc. (NYSE:USPH)

Proficio Capital Partners LLC purchased a new position in U.S. Physical Therapy, Inc. (NYSE:USPH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 39,742 shares of the company's stock, valued at approximately $3,526,000. Proficio Capital Partners LLC owned approximately 0.26% of U.S. Physical Therapy as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Albert D Mason Inc. increased its holdings in U.S. Physical Therapy by 1.3% in the 4th quarter. Albert D Mason Inc. now owns 10,596 shares of the company's stock worth $940,000 after acquiring an additional 139 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in U.S. Physical Therapy by 1.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 16,344 shares of the company's stock worth $1,450,000 after acquiring an additional 156 shares in the last quarter. Illinois Municipal Retirement Fund increased its holdings in U.S. Physical Therapy by 3.6% in the 4th quarter. Illinois Municipal Retirement Fund now owns 8,351 shares of the company's stock worth $741,000 after acquiring an additional 292 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in U.S. Physical Therapy by 25.1% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,486 shares of the company's stock worth $126,000 after acquiring an additional 298 shares in the last quarter. Finally, KBC Group NV increased its holdings in U.S. Physical Therapy by 68.6% in the 3rd quarter. KBC Group NV now owns 774 shares of the company's stock worth $66,000 after acquiring an additional 315 shares in the last quarter.

Remove Ads

U.S. Physical Therapy Trading Down 2.9 %

Shares of USPH stock traded down $2.37 on Friday, hitting $80.61. 155,339 shares of the stock traded hands, compared to its average volume of 105,621. The firm's 50-day moving average price is $87.42 and its two-hundred day moving average price is $87.51. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.78 and a current ratio of 1.78. The stock has a market capitalization of $1.22 billion, a PE ratio of 85.76, a PEG ratio of 3.54 and a beta of 1.48. U.S. Physical Therapy, Inc. has a twelve month low of $76.18 and a twelve month high of $113.63.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.04). The firm had revenue of $180.45 million for the quarter, compared to analyst estimates of $173.10 million. U.S. Physical Therapy had a net margin of 3.54% and a return on equity of 8.11%. As a group, analysts anticipate that U.S. Physical Therapy, Inc. will post 2.67 EPS for the current year.

U.S. Physical Therapy Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 11th. Stockholders of record on Friday, March 14th will be given a dividend of $0.45 per share. This is a boost from U.S. Physical Therapy's previous quarterly dividend of $0.44. The ex-dividend date is Friday, March 14th. This represents a $1.80 annualized dividend and a dividend yield of 2.23%. U.S. Physical Therapy's payout ratio is presently 97.83%.

Wall Street Analysts Forecast Growth

USPH has been the subject of several recent analyst reports. Bank of America raised shares of U.S. Physical Therapy from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $100.00 to $115.00 in a report on Monday, December 16th. Citizens Jmp raised shares of U.S. Physical Therapy to a "strong-buy" rating in a research note on Monday, December 16th. Barrington Research lowered their target price on shares of U.S. Physical Therapy from $108.00 to $98.00 and set an "outperform" rating on the stock in a research note on Friday, February 28th. JMP Securities started coverage on shares of U.S. Physical Therapy in a research note on Monday, December 16th. They set an "outperform" rating and a $113.00 target price on the stock. Finally, William Blair reaffirmed a "market perform" rating on shares of U.S. Physical Therapy in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $111.50.

Insider Activity

In other U.S. Physical Therapy news, CFO Carey P. Hendrickson sold 516 shares of the company's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $96.25, for a total value of $49,665.00. Following the transaction, the chief financial officer now owns 20,469 shares of the company's stock, valued at $1,970,141.25. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Graham D. Reeve sold 1,730 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $82.11, for a total transaction of $142,050.30. Following the completion of the transaction, the chief operating officer now directly owns 7,168 shares in the company, valued at $588,564.48. The trade was a 19.44 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company's stock.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.